Gene Solutions concluded the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore (5–7 December) with a focus on AI-driven liquid biopsy technologies. The company presented seven scientific abstracts and earned two Best Poster awards for its research on colorectal cancer screening and allogenic cell therapy.

• Multicancer Early Detection (SPOT-MAS): Real-world data from over 12,000 individuals demonstrated 78.2% sensitivity and 99.8% specificity for 10 common cancers. The assay uses a single 10 mL blood draw to analyse genetic, epigenetic, and fragmentomic features via shallow whole-genome sequencing.
• Molecular Residual Disease (K-TRACK): A real-world study of 623 patients confirmed that ctDNA-MRD monitoring could detect cancer relapse up to 14 months earlier than conventional imaging across multiple solid tumours.
• Comprehensive Profiling (K-4CARE): This platform integrates DNA and transcriptomic (RNA) profiling to improve fusion detection and predict the primary site for Cancers of Unknown Primary (CUP) with 87.7% prediction accuracy.
• Scientific Recognition: The “Best Poster” awards were granted for studies on integrated cfRNA + ctDNA for colorectal screening (Trang T. Tran) and a scalable NK cell platform for solid tumours (Thu Dao).

This summary is based on a press release issued by Gene Solutions.